Key result
Conjugated linoleic acid supplementation significantly reduced body weight by a mean of 0.72 kg compared to control in patients at risk of cardiovascular disease, with no significant effect on lipid profiles or blood pressure.
Why the study?
The study sought to evaluate the effects of conjugated linoleic acid (CLA) supplementation on cardiovascular risk factors in patients at risk of CVD.
Does conjugated linoleic acid (CLA) supplementation improve cardiovascular risk factors in patients at risk of cardiovascular disease?
Meta-Analysis (n=772)
Does conjugated linoleic acid (CLA) supplementation improve cardiovascular risk factors in patients at risk of cardiovascular disease?
Answers are grounded in this paper and cite their sources.
CLA supplementation yields a small but statistically significant reduction in body weight, BMI, and body fat percentage in patients at risk of CVD, though these changes may not be clinically important.
The present systematic review and meta-analysis sought to evaluate the effects of conjugated linoleic acid (CLA) supplementation on cardiovascular risk factors in patients at risk of CVD. Relevant studies were obtained by searching the PubMed, SCOPUS and Web of Science databases (from inception to January 2023). Weighted mean differences (WMD) and 95% CI were pooled using a random-effects model. Heterogeneity, sensitivity analysis and publication bias were reported using standard methods. A pooled analysis of 14 randomised controlled trials (RCT) with 17 effect sizes revealed that CLA supplementation led to significant reductions in body weight (WMD: −0·72 kg, 95% CI: −1·11, −0·33, P < 0·001), BMI (WMD: −0·22 kg/m2, 95% CI: −0·44, −0·00, P = 0·037) and body fat percentage (BFP) (WMD: −1·32 %, 95% CI: −2·24, −0·40, P = 0·005). However, there was no effect on lipid profile and blood pressure in comparison with the control group. In conclusion, CLA supplementation may yield a small but significant beneficial effect on anthropometric indices in patients at risk of CVD. Moreover, CLA seems not to have adverse effects on lipid profiles and blood pressure in patients at risk of CVD. It should be noted that the favourable effects of CLA supplementation on anthropometric variables were small and may not reach clinical importance.
No takes yet. Share an insight, caveat, or question.
Esmaeilnejad et al. (2024) conducted a meta-analysis in Patients at risk of cardiovascular disease (n=772). Conjugated linoleic acid (CLA) vs. Placebo or control diet was evaluated on Body weight (WMD -0.72 kg, 95% CI -1.11 to -0.33, p=<0.001). Conjugated linoleic acid supplementation significantly reduced body weight by a mean of 0.72 kg compared to control in patients at risk of cardiovascular disease, with no significant effect on lipid profiles or blood pressure.
Synapse has enriched 10 related papers. Consider them for comparative context: